Big Pharma’s Patent Abuses Are Fueling the Drug Pricing Crisis
The latest in news from I-MAK experts.
For press inquiries, please contact simon@i-mak.org.
Abbott Abandons Several Patent Applications in India
Indian political will to be put to the test as Cipla seeks Isentress voluntary license
Tahir Amin Speaks to NDTV About the Recent Victory Against Abbott Laboratories HIV Drug Patent
WTO, WIPO and WHO Examine Role of Patent Information in Access to Medicines
Drug company’s loss could be Africa’s gain
India rejects US company’s patent for anti-HIV drugs
Top 5 Global Health Headlines: India Rejects HIV Patent
India has rejected a patent application for Abbott’s HIV/AIDS treatment Kaletra, reigniting a debate over the country’s patent rules.
Indian Government Rejects Abbott’s Patent Application For Second-Line ARV
HIV Drug to Be Distributed Worldwide